A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

被引:78
|
作者
Pillans, PI
Rigby, RJ
Kubler, P
Willis, C
Salm, P
Tett, SE
Taylor, PJ
机构
[1] Princess Alexandra Hosp, Dept Clin Pharmacol, Woolloongabba, Qld 4102, Australia
[2] Univ Queensland, Princess Alexandra Hosp, Dept Med, Brisbane, Qld 4102, Australia
[3] Princess Alexandra Hosp, Renal Transplantat Unit, Woolloongabba, Qld 4102, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia
关键词
mycophenolic acid; cyclosporin; acute rejection; renal transplantation;
D O I
10.1016/S0009-9120(00)00196-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objectives: Although monitoring of cyclosporin (CsA) is standard clinical practice postrenal transplantation. mycophenolic acid (MPA) concentrations are not routinely measured. There is evidence that a relationship exists between MPA area under the concentration-time curve (AUC) and rejection. In this study, a retrospective analysis was undertaken of 27 adult renal transplant recipients. Methods: Patients received CsA and MPA therapy and had a four-point MPA AUC investigation. The relationship between MPA AUC performed in the first week after transplantation, as well as median trough cyclosporin concentrations, and clinical outcomes in the first month posttransplant were evaluated. Results: A total of 12 patients experienced biopsy proven rejection (44.4%) and 4 patients had gastrointestinal adverse events (14.8%). A statistically significant relationship was observed between the incidence of biopsy proven rejection and both MPA AUC (p = 0.02) and median trough CsA concentration (p = 0.008). No relationship between trough MPA concentration and rejection was observed (p = 0.21). Only 3 of 11 (27%) patients with an MPA AUC > 30 mg.h/L and a median trough CsA > 175 mug/L experienced acute rejection, compared with a 56% incidence of rejection for the remaining 16 patients. Patients who experienced adverse gastrointestinal events had significantly lower MPA AUC (p = 0.04), but median trough CsA concentrations were not significantly different (p = 0.24). Further, 3 of these 4 patients had rejection episodes. Conclusions: in addition to standard CsA monitoring, we propose further investigation of the use of a 4-point sampling strategy to predict MPA AUC in the first week posttransplant, which may facilitate optimization of mycophenolate mofetil dose at a rime when patients are most vulnerable to acute rejection. (C) 2001 The Canadian Society of Clinical Chemists. All rights reserved.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 50 条
  • [31] Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid
    van Gelder, Teun
    Silva, Helio Tedesco
    de Fijter, Johan W.
    Budde, Klemens
    Kuypers, Dirk
    Arns, Wolfgang
    Soulillou, Jean Paul
    Kanellis, John
    Zelvys, Arunas
    Ekberg, Henrik
    Holzer, Herwig
    Rostaing, Lionel
    Mamelok, Richard D.
    TRANSPLANTATION, 2010, 89 (05) : 595 - 599
  • [32] Detection of acute rejection by proteomic analysis of urinary samples in renal transplant recipients
    Wittke, S
    Haubitz, M
    Walden, M
    Rohde, F
    Mengel, ASM
    Mischak, H
    Gwinner, W
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V158 - V159
  • [33] Corticosteroid Withdrawal in Renal Transplant Recipients: Two-Year Analysis of the Mycophenolic Acid Observational Renal Transplant (MORE) Registry
    Ueda, K.
    Wiland, A.
    Mccague, K.
    Peddi, V. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 493 - 494
  • [34] Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection
    Cantin, B
    Giannetti, N
    Parekh, H
    Panchal, SN
    Kwok, BWK
    Najem, R
    Woodman, K
    Hunt, SA
    Valantine, HA
    CLINICAL TRANSPLANTATION, 2002, 16 (03) : 196 - 201
  • [35] TREATMENT OF ACUTE REJECTION IN RENAL GRAFT RECIPIENTS BY THYMOGLOBULINE - A RETROSPECTIVE MULTICENTER ANALYSIS
    BOCK, P
    HOBLER, N
    CAUDRELIER, P
    ALBERICI, G
    TRANSPLANTATION PROCEEDINGS, 1995, 27 (01) : 1058 - 1059
  • [36] DIFFERENTIATION BETWEEN ALLOGRAFT-REJECTION AND CYCLOSPORIN NEPHROTOXICITY IN RENAL-TRANSPLANT RECIPIENTS
    TAUBE, DH
    WILLIAMS, DG
    HARTLEY, B
    RUDGE, CJ
    NEILD, GH
    CAMERON, JS
    OGG, CS
    WELSH, KI
    LANCET, 1985, 2 (8448): : 171 - 174
  • [37] Evaluation of acute kidney rejection in 230 renal transplant recipients
    Khajehmugehi, AR
    Mehrsai, AR
    Taheri, M
    Khan, ZH
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (03) : 730 - 731
  • [38] Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients
    Merkel, U
    Lindner, S
    Vollandt, R
    Sperschneider, H
    Balogh, A
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2005, 43 (08) : 379 - 388
  • [39] PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS RECEIVING ORALMYCOPHENOLATE MOFETIL
    Cornelissen, Elisabeth A. M.
    Schreuder, Michiel
    Jacobs, Bart
    Aarnoutse, Rob
    Bruggemann, Roger
    PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1823 - 1824
  • [40] Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
    Langman, LJ
    LeGatt, DF
    Halloran, PF
    Yatscoff, RW
    TRANSPLANTATION, 1996, 62 (05) : 666 - 672